Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.55 |
| ▸ | DPP4 | P27487 | 3/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.47 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25129445 | 1.00 | FKBP1A (0.55) | FKBP1ADPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL7275982 | 0.99 | FKBP1A (0.54) | FKBP1ADPP4DPP8DPP9DPP7 | |
| Trifluoroacetic Acid SCHEMBL29286206 | 0.94 | FKBP1A (0.50) | FKBP1ADPP4DPP8DPP9DPP7 | |
| SCHEMBL38652282 | 0.89 | FKBP1A (0.53) | FKBP1ADPP4DPP8DPP9DPP7 | |
| SCHEMBL8365666 | 0.89 | DPP4 (0.61) | FKBP1ADPP4DPP8DPP9DPP7 | |
| SCHEMBL7508784 | 0.89 | DPP4 (0.61) | FKBP1ADPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL38652210 | 0.88 | FKBP1A (0.53) | FKBP1ADPP4DPP8DPP9DPP7 | |
| SCHEMBL13413212 | 0.88 | FKBP1A (0.57) | FKBP1ADPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL10403931 | 0.88 | DPP4 (0.60) | FKBP1ADPP4DPP8DPP9DPP7 | |
| SCHEMBL29290357 | 0.88 | FKBP1A (0.56) | FKBP1ADPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2025-01-30 | — | — | US | disclosed |
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | LERCHEN, HANS-GEORG (DE) | 2024-12-26 | — | — | US | disclosed |
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| CN-118556062-A | Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders | 文赛克斯制药有限责任公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-4412655-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| EP-4412656-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| EP-0345867-A1 | Novel synthetic, immunologically active peptides useful for the preparation of antimalarial vaccines | ENIRICERCHE S.p.A. (IT) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | PCNA, TP53, BRCA1 | FKBP1A 2391/4885DPP4 3481/4885DPP8 1455/4885 |
| US-20250032477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | PCNA, TOP1, TOP2A | FKBP1A 885/4885DPP4 2583/4885DPP8 1366/4885 |
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | PTK2, PCNA, CDK4 | FKBP1A 1234/4885DPP4 2281/4885DPP8 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.